Abstract
In recent years, China has paid much more attention to its pharmaceutical policy than ever, and forecasting policy on pharmaceutical patent protection has become a public concern in China. This article reviews the history and development of policy on pharmaceutical patent protection and reveals the existing problems in patent protection for pharmaceutical research and development companies. By focusing on the relationship among national policies, patent application, and invalidation of patents from pharmaceutical research and development companies and generic drug companies, the article analyzes the interaction between pharmaceutical policies and raised critical issues on how to advance innovation to promote society welfare. The article concludes by discussing pharmaceutical patent policy trends and future developments.
Get full access to this article
View all access options for this article.